Short answer: Retatrutide has a half-life of about 6 days (144 hours). After about 5 half-lives, roughly 97% of a dose is gone, so it is mostly cleared about 30 days (720 hours) after the last dose. People vary, so treat these as estimates.
What is retatrutide?
Retatrutide (LY3437943) is an investigational drug from Eli Lilly that acts on GIP, GLP-1 and glucagon receptors. It is not FDA approved as of October 2026.
Also known as: LY3437943.
Common vial sizes
There is no approved retatrutide product. Powder vials are most often labeled 10 mg, 20 mg or 30 mg; 5 mg, 15 mg, 40 mg, 50 mg and 60 mg vials are also common.
Water and syringe-unit charts by vial size: 5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 40 mg · 50 mg · 60 mg
Worked reconstitution example
Here is the math for a 10 mg vial mixed with 2 mL of bacteriostatic water, drawing 2 mg with a U-100 insulin syringe (1 mL = 100 units).
- Concentration.
10 mg ÷ 2 mL = 5 mg/mL - Volume to draw.
2 mg ÷ 5 mg/mL = 0.4 mL - Syringe units.
0.4 mL × 100 = 40 units
Units chart at 5 mg/mL
| Amount | Volume | U-100 syringe |
|---|---|---|
| 1 mg | 0.2 mL | 20 units |
| 2 mg | 0.4 mL | 40 units |
| 4 mg | 0.8 mL | 80 units |
Same amount, different water volumes
Adding more water doesn't change how much retatrutide is in the vial. It only spreads it over more liquid, so each draw is bigger and easier to read.
| Water added | Concentration | Volume | U-100 syringe |
|---|---|---|---|
| 1 mL | 10 mg/mL | 0.2 mL | 20 units |
| 2 mL | 5 mg/mL | 0.4 mL | 40 units |
| 3 mL | 3.33 mg/mL | 0.6 mL | 60 units |
| 5 mL | 2 mg/mL | 1 mL | 100 units |
For any other vial size or amount, the free peptide reconstitution calculator works backwards from the amount you want and suggests a water volume that lands on a clean syringe mark.
What doses of retatrutide were studied?
Retatrutide is given once a week. In the phase 2 obesity trial (Jastreboff, NEJM 2023; 338 adults, 48 weeks), people were randomized to placebo or 1, 4, 8 or 12 mg. The higher doses were reached by stepping up every 4 weeks: 4 mg started at 2 or 4 mg, 8 mg went 2 → 4 → 8 or 4 → 8, and 12 mg went 2 → 4 → 8 → 12.
| Group | Week 24 | Week 48 |
|---|---|---|
| Placebo | −1.6% | −2.1% |
| 1 mg | −7.2% | −8.7% |
| 4 mg | −12.9% | −17.1% |
| 8 mg | −17.3% | −22.8% |
| 12 mg | −17.5% | −24.2% |
In the phase 2 type 2 diabetes trial (Rosenstock, Lancet 2023; 281 adults, 36 weeks), arms ran from 0.5 mg to 12 mg, including 4 mg and 8 mg arms with different escalation speeds, against placebo and dulaglutide 1.5 mg. At 24 weeks HbA1c fell by 2.02 percentage points on 12 mg versus 1.41 on dulaglutide; body weight fell 16.94% on 12 mg at 36 weeks.
The phase 3 TRIUMPH trials test 4, 9 and 12 mg once weekly. Everyone starts at 2 mg and steps up every 4 weeks through 2, 4, 6, 9 and 12 mg until reaching their assigned dose, then stays there.
Where is retatrutide in approval?
As of October 17, 2026, retatrutide is not approved in any country. Eli Lilly has said it plans to submit it to the FDA in the first quarter of 2027. Phase 3 results so far (mean weight change on the efficacy estimand, versus placebo):
- TRIUMPH-4 (announced December 11, 2025; 445 adults with obesity and knee osteoarthritis, 68 weeks): −26.4% on 9 mg and −28.7% on 12 mg, versus −2.1%.
- TRANSCEND-T2D-1 (March 19, 2026; 537 adults with type 2 diabetes, 40 weeks): HbA1c −1.7, −2.0 and −1.9 points on 4, 9 and 12 mg versus −0.8; weight −11.5%, −15.5% and −16.8% versus −2.5%.
- TRIUMPH-1 (May 21, 2026; 2,339 adults, 80 weeks; published in NEJM September 29, 2026): −19.0%, −25.9% and −28.3% on 4, 9 and 12 mg, versus −2.2%.
- TRIUMPH-2 (July 23, 2026; 1,152 adults with obesity and type 2 diabetes): −12.7%, −19.1% and −20.8% on 4, 9 and 12 mg, versus −4.0%.
- TRIUMPH-3 (July 23, 2026; 1,949 adults with a BMI of 35 or more and cardiovascular disease): −21.6% on 9 mg and −22.6% on 12 mg, versus −3.2%.
Until there is an approved product, there is no FDA label with dosing, storage or safety instructions. For how retatrutide compares with tirzepatide, see retatrutide vs tirzepatide.
How many units is X mg of retatrutide?
It depends only on the concentration in your vial. The table shows syringe units on a U-100 insulin syringe (1 mL = 100 units) at four common vial and water combinations. The amounts are the doses used in the trials above, shown for the conversion only.
| Amount | 5 mg + 2 mL (2.5 mg/mL) | 10 mg + 2 mL (5 mg/mL) | 20 mg + 2 mL (10 mg/mL) | 30 mg + 2 mL (15 mg/mL) |
|---|---|---|---|---|
| 1 mg | 40 units | 20 units | 10 units | 6.7 units |
| 2 mg | 80 units | 40 units | 20 units | 13.3 units |
| 4 mg | over 1 mL | 80 units | 40 units | 26.7 units |
| 6 mg | over 1 mL | over 1 mL | 60 units | 40 units |
| 8 mg | over 1 mL | over 1 mL | 80 units | 53.3 units |
| 9 mg | over 1 mL | over 1 mL | 90 units | 60 units |
| 12 mg | over 1 mL | over 1 mL | over 1 mL | 80 units |
Formula: amount ÷ (vial mg ÷ water mL) × 100 = units. For any other vial or water volume, use the reconstitution calculator, or see the GLP-1 units guide.
Retatrutide half-life and time to peak
- Half-lifeabout 6 days (144 hours)
- Time to peak (Tmax)Not listed
- Route in Dose TrackUnder the skin (subcutaneous)
A phase 1b trial (Urva 2022) reported a half-life of about 6 days. We could not confirm a published time to peak, so we leave it out.
Numbers shown are the values Dose Track uses, listed only where they agree with the source above. Half-life varies from person to person and with injection site.
How to track retatrutide in Dose Track
- Add retatrutide from the built-in list. It sits next to everything else you take, so a GLP-1, TRT and a few peptides all live in one log.
- Save your vial: enter the vial size and how much water you added. From then on every amount you log shows as syringe units, and the reconstitution planner suggests a water volume that lands on a clean mark.
- Log each shot. The app subtracts it from the vial, shows what is left, and warns you before you run out.
- Set reminders on your own schedule, whether that is daily, weekly or every few days.
- Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.
Retatrutide tracker · How Dose Track handles GLP-1s · Reconstitution calculator · Half-life calculator
Related compounds
Frequently asked questions
How much bacteriostatic water do I add to a 10 mg retatrutide vial?+
How many units is 2 mg of retatrutide?+
What is the half-life of retatrutide?+
What doses of retatrutide were studied in trials?+
Is retatrutide FDA approved?+
Can I track retatrutide in Dose Track?+
Sources
- Urva S, et al. LY3437943 (retatrutide) in people with type 2 diabetes: a phase 1b multiple-ascending dose trial. Lancet. 2022.
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
- Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet. 2023;402:529-544.
- TRIUMPH phase 3 program design and rationale. Diabetes Obes Metab. 2026;28(1):83-93.
- Eli Lilly press release: retatrutide phase 3 data presentations (June 6, 2026).
- Eli Lilly press release: TRIUMPH-4 topline results (December 11, 2025).
- Eli Lilly press release: TRANSCEND-T2D-1 topline results (March 19, 2026).
- Eli Lilly press release: TRIUMPH-1 topline results (May 21, 2026).
- TRIUMPH-1: retatrutide for obesity, phase 3. N Engl J Med. Published online September 29, 2026.
- Eli Lilly press release: TRIUMPH-2 and TRIUMPH-3 topline results and submission plans (July 23, 2026).
- TRIUMPH-2: retatrutide in people with obesity and type 2 diabetes, phase 3. Lancet. 2026;408:1455.